Abstract
A current goal in molecular medicine is the development of new strategies for the selective inhibition of cancer-critical genes. Triplex-forming oligonucleotides and peptide nucleic acids bind to the double helix of DNA in a sequence-specific manner and with great affinity. Because of these properties, these molecules have been proposed as anti-gene therapeutic drugs. This review summarizes recent results on the use of oligonucleotides and peptide nucleic acids to downregulate gene expression in cultured cells. The data are discussed from the perspective of the recent literature on new molecular strategies with potential therapeutic applications.
Keywords: triple-helix oligonucleotides, peptide nucleic acid, antigene strategies, peg-conjugated tfo, cell cultures, oncogenes
Current Pharmaceutical Design
Title: Anti-Gene Strategies to Down-Regulate Gene Expression in Mammalian Cells
Volume: 10 Issue: 7
Author(s): L. E. Xodo, S. Cogoi and V. Rapozzi
Affiliation:
Keywords: triple-helix oligonucleotides, peptide nucleic acid, antigene strategies, peg-conjugated tfo, cell cultures, oncogenes
Abstract: A current goal in molecular medicine is the development of new strategies for the selective inhibition of cancer-critical genes. Triplex-forming oligonucleotides and peptide nucleic acids bind to the double helix of DNA in a sequence-specific manner and with great affinity. Because of these properties, these molecules have been proposed as anti-gene therapeutic drugs. This review summarizes recent results on the use of oligonucleotides and peptide nucleic acids to downregulate gene expression in cultured cells. The data are discussed from the perspective of the recent literature on new molecular strategies with potential therapeutic applications.
Export Options
About this article
Cite this article as:
Xodo E. L., Cogoi S. and Rapozzi V., Anti-Gene Strategies to Down-Regulate Gene Expression in Mammalian Cells, Current Pharmaceutical Design 2004; 10 (7) . https://dx.doi.org/10.2174/1381612043452983
DOI https://dx.doi.org/10.2174/1381612043452983 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Applications of Nanosystems to Anticancer Drug Therapy (Part II. Dendrimers, Micelles, Lipid-based Nanosystems)
Recent Patents on Anti-Cancer Drug Discovery The Function and Regulation of BMP6 in Various Kinds of Stem Cells
Current Pharmaceutical Design Lymphatics and Inflammation
Current Medicinal Chemistry ABC Transporters in Multidrug Resistance and Pharmacokinetics, and Strategies for Drug Development
Current Pharmaceutical Design 3-Hydroxy-2-phenyl-4(1H)-quinolinones as Promising Biologically Active Compounds
Mini-Reviews in Medicinal Chemistry HDAC Inhibitors as Novel Anti-Cancer Therapeutics
Recent Patents on Anti-Cancer Drug Discovery Monoclonal Antibody Therapy in Haematological Malignancies
Current Clinical Pharmacology Design of New Drug Molecules to be Used in Reversing Multidrug Resistance in Cancer Cells
Current Cancer Drug Targets Self-Assembling Peptides: Potential Role in Tumor Targeting
Current Pharmaceutical Biotechnology Pluripotency and Targeted Reprogramming: Strategies, Disease Modeling and Drug Screening
Current Drug Delivery Germinal and Somatic Trisomy 21 Mosaicism: How Common is it, What are the Implications for Individual Carriers and How Does it Come About?
Current Genomics Serine-Threonine Protein Kinases CK1, CK2 and GSK3 in Normal and Malignant Haematopoiesis
Current Signal Transduction Therapy The Coordinated Role of CYP450 Enzymes and P-gp in Determining Cancer Resistance to Chemotherapy
Current Drug Metabolism Muscarinic Acetylcholine Receptor-Interacting Proteins (mAChRIPs): Targeting the Receptorsome
Current Drug Targets Chemical Space of FLT3 Inhibitors as Potential Anti-AML Drugs
Recent Patents on Anti-Cancer Drug Discovery Emerging Role of Wnt/Beta-Catenin Signalling Pathways in Cancer Progression and Role of Small Molecule Tankyrase Inhibitors in Combating Multistage Cancers
Current Cancer Therapy Reviews Metabolomics Applications in Precision Medicine: An Oncological Perspective
Current Topics in Medicinal Chemistry Critical Roles of EGFR Family Members in Breast Cancer and Breast Cancer Stem Cells: Targets for Therapy
Current Pharmaceutical Design IMGT Colliers de Perles: Standardized Sequence-Structure Representations of the IgSF and MhcSF Superfamily Domains
Current Bioinformatics Pertinence of Apoptosis Markers for the Improvement of In Vitro Fertilization (IVF)
Current Medicinal Chemistry